Christiane A Opitz

List of Publications by Year
in descending order

60 papers	6,108 citations	136740 32 h-index	149479 56 g-index
64 all docs	64 docs citations	64 times ranked	9028 citing authors

#	Article	IF	Citations
1	cDC1 to cDC2: â€œEverything I do, Ido1 it for youâ€• Immunity, 2022, 55, 967-970.	6.6	1
2	From anti-aging drugs to cancer therapy: is there a potential for sirtuin activators in gliomas?. Neuro-Oncology, 2021, 23, 3-5.	0.6	2
3	Hypoxia Routes Tryptophan Homeostasis Towards Increased Tryptamine Production. Frontiers in Immunology, 2021, 12, 590532.	2.2	6
4	G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling. Cell, 2021, 184, 655-674.e27.	13.5	65
5	Tryptophan metabolism in brain tumors â€" IDO and beyond. Current Opinion in Immunology, 2021, 70, 57-66.	2.4	30
6	Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. Theranostics, 2021, 11, 9217-9233.	4.6	16
7	ID3 promotes homologous recombination via non-transcriptional and transcriptional mechanisms and its loss confers sensitivity to PARP inhibition. Nucleic Acids Research, 2021, 49, 11666-11689.	6.5	8
8	The TSC Complex-mTORC1 Axis: From Lysosomes to Stress Granules and Back. Frontiers in Cell and Developmental Biology, 2021, 9, 751892.	1.8	22
9	Hypoxia decreases the T helper cell-suppressive capacity of synovial fibroblasts by downregulating IDO1-mediated tryptophan metabolism. Rheumatology, 2020, 59, 1148-1158.	0.9	12
10	The therapeutic potential of targeting tryptophan catabolism in cancer. British Journal of Cancer, 2020, 122, 30-44.	2.9	159
11	IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell, 2020, 182, 1252-1270.e34.	13.5	259
12	Hepatocyte-intrinsic type I interferon signaling reprograms metabolism and reveals a novel compensatory mechanism of the tryptophan-kynurenine pathway in viral hepatitis. PLoS Pathogens, 2020, 16, e1008973.	2.1	6
13	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine, 2020, 9, 8373-8385.	1.3	19
14	Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis, 2020, 9, 102.	2.1	24
15	Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPÎ². Frontiers in Immunology, 2020, 11, 657.	2.2	24
16	Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nature Communications, 2020, 11, 931.	5.8	112
17	Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology. Nature Communications, 2019, 10, 4877.	5.8	69
18	Resistance Exercise Reduces Kynurenine Pathway Metabolites in Breast Cancer Patients Undergoing Radiotherapy. Frontiers in Oncology, 2019, 9, 962.	1.3	35

#	Article	IF	Citations
19	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nature Reviews Drug Discovery, 2019, 18, 379-401.	21.5	805
20	Hypoxia Inducible Factor 1Î± Inhibits the Expression of Immunosuppressive Tryptophan-2,3-Dioxygenase in Glioblastoma. Frontiers in Immunology, 2019, 10, 2762.	2.2	22
21	The PI3K and MAPK/p38 pathways control stress granule assembly in a hierarchical manner. Life Science Alliance, 2019, 2, e201800257.	1.3	49
22	Fourier Transform Infrared Microscopy Enables Guidance of Automated Mass Spectrometry Imaging to Predefined Tissue Morphologies. Scientific Reports, 2018, 8, 313.	1.6	37
23	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro-Oncology, 2018, 20, 367-379.	0.6	79
24	Upregulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degradation. OncoImmunology, 2018, 7, e1486353.	2.1	62
25	Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. OncoImmunology, 2017, 6, e1274477.	2.1	30
26	Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. Scientific Reports, 2017, 7, 41271.	1.6	53
27	Synovial Fibroblasts Selectively Suppress Th1 Cell Responses through IDO1-Mediated Tryptophan Catabolism. Journal of Immunology, 2017, 198, 3109-3117.	0.4	27
28	Suppression of Th1 differentiation by tryptophan supplementation in vivo. Amino Acids, 2017, 49, 1169-1175.	1.2	23
29	Epigenetic regulation of indoleamine-2,3-dioxygenase 1 expression in human breast cancer. Breast, 2017, 32, S31-S32.	0.9	0
30	Measuring tryptophan concentrations of aqueous solutions for cancer research using terahertz time-domain spectroscopy with metal parallel-plate waveguides. , 2017, , .		0
31	Quantitative Analysis of Proteome Modulations in Alveolar Epithelial Type II Cells in Response to Pulmonary Aspergillus fumigatus Infection. Molecular and Cellular Proteomics, 2017, 16, 2184-2198.	2.5	26
32	AB0068â€…Hypoxia and rheumatoid phenotype decrease the capacity of synovial fibroblasts to suppress t helper cell proliferation through ido1-mediated tryptophan catabolism. , 2017, , .		0
33	04.11â€…Hypoxia and rheumatoid phenotype prevent synovial fibroblasts from suppressing t helper cell proliferation through ido1-mediated tryptophan metabolism. , 2017, , .		0
34	Tryptophanâ€2,3â€dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptorâ€4. Journal of Neurochemistry, 2016, 136, 1142-1154.	2.1	48
35	The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. OncoImmunology, 2016, 5, e1240858.	2.1	51
36	Dynamics of NAD-metabolism: everything but constant. Biochemical Society Transactions, 2015, 43, 1127-1132.	1.6	45

#	Article	IF	Citations
37	A1.28â€...Synovial fibroblasts suppress TH1, but not TH2 or TH17 cells, through tryptophan metabolism. Annals of the Rheumatic Diseases, 2015, 74, A12.1-A12.	0.5	0
38	Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia, 2015, 63, 78-90.	2.5	51
39	O6.09 * PROSTAGLANDIN E RECEPTOR-4 ACTIVATION REGULATES TRYPTOPHAN METABOLISM IN HUMAN MALIGNANT GLIOMAS. Neuro-Oncology, 2014, 16, ii14-ii14.	0.6	0
40	Microenvironmental Clues for Glioma Immunotherapy. Current Neurology and Neuroscience Reports, 2014, 14, 440.	2.0	51
41	Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget, 2014, 5, 1038-1051.	0.8	248
42	The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress. Cancer Research, 2013, 73, 3225-3234.	0.4	126
43	Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. Journal of Neuroimmunology, 2013, 265, 106-116.	1.1	81
44	Protein kinase CÎ² as a therapeutic target stabilizing bloodâ€"brain barrier disruption in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14735-14740.	3.3	43
45	The aryl hydrocarbon receptor as a promoter of malignant glioma. Cell Cycle, 2012, 11, 643-644.	1.3	4
46	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 2011, 478, 197-203.	13.7	1,514
47	Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. Biochemical Pharmacology, 2011, 82, 632-641.	2.0	41
48	The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells. PLoS ONE, 2011, 6, e19823.	1.1	126
49	Mouse Mesenchymal Stem Cells Suppress Antigen-Specific TH Cell Immunity Independent of Indoleamine 2,3-Dioxygenase 1 (IDO1). Stem Cells and Development, 2010, 19, 657-668.	1.1	49
50	Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-Î² and Protein Kinase R Â. Stem Cells, 2009, 27, 909-919.	1.4	268
51	Painful neuropathy due to intraneural leukemic spread in a patient with acute myeloid leukemia. Neurology, 2007, 69, 707-707.	1.5	14
52	Pirfenidone inhibits TGF-Î² expression in malignant glioma cells. Biochemical and Biophysical Research Communications, 2007, 354, 542-547.	1.0	72
53	Production of the endocannabinoids anandamide and 2â€arachidonoylglycerol by endothelial progenitor cells. FEBS Letters, 2007, 581, 4927-4931.	1.3	33
54	Tryptophan degradation in autoimmune diseases. Cellular and Molecular Life Sciences, 2007, 64, 2542-2563.	2.4	95

#	Article	IF	Citations
55	Plasticity of cardiac titin/connectin in heart development. Journal of Muscle Research and Cell Motility, 2006, 26, 333-342.	0.9	26
56	Isoform Diversity of Giant Proteins in Relation to Passive and Active Contractile Properties of Rabbit Skeletal Muscles. Journal of General Physiology, 2005, 126, 461-480.	0.9	284
57	Developmentally Regulated Switching of Titin Size Alters Myofibrillar Stiffness in the Perinatal Heart. Circulation Research, 2004, 94, 967-975.	2.0	177
58	Passive Stiffness Changes Caused by Upregulation of Compliant Titin Isoforms in Human Dilated Cardiomyopathy Hearts. Circulation Research, 2004, 95, 708-716.	2.0	300
59	Gigantic variety: expression patterns of titin isoforms in striated muscles and consequences for myofibrillar passive stiffness. Journal of Muscle Research and Cell Motility, 2003, 24, 175-189.	0.9	167
60	Damped elastic recoil of the titin spring in myofibrils of human myocardium. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12688-12693.	3.3	105